Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Survey of distribution of seasonal influenza vaccine doses in 201 countries (2004-2015): The 2003 World Health Assembly resolution on seasonal influenza vaccination coverage and the 2009 influenza pandemic have had very little impact on improving influenza control and pandemic preparedness.

Palache A, Abelin A, Hollingsworth R, Cracknell W, Jacobs C, Tsai T, Barbosa P; IFPMA Influenza Vaccine Supply (IFPMA IVS) task force.

Vaccine. 2017 Aug 24;35(36):4681-4686. doi: 10.1016/j.vaccine.2017.07.053. Epub 2017 Jul 25.

PMID:
28754488
2.

Rationale for two influenza B lineages in seasonal vaccines: A meta-regression study on immunogenicity and controlled field trials.

Beyer WEP, Palache AM, Boulfich M, Osterhaus ADME.

Vaccine. 2017 Jul 24;35(33):4167-4176. doi: 10.1016/j.vaccine.2017.06.038. Epub 2017 Jun 24.

PMID:
28655451
3.

Seasonal influenza vaccine dose distribution in 195 countries (2004-2013): Little progress in estimated global vaccination coverage.

Palache A, Oriol-Mathieu V, Fino M, Xydia-Charmanta M; Influenza Vaccine Supply task force (IFPMA IVS).

Vaccine. 2015 Oct 13;33(42):5598-5605. doi: 10.1016/j.vaccine.2015.08.082. Epub 2015 Sep 11.

4.

Seasonal influenza vaccine dose distribution in 157 countries (2004-2011).

Palache A, Oriol-Mathieu V, Abelin A, Music T; Influenza Vaccine Supply task force (IFPMA IVS).

Vaccine. 2014 Nov 12;32(48):6369-76. doi: 10.1016/j.vaccine.2014.07.012. Epub 2014 Nov 1. Review.

5.

Antibody landscapes after influenza virus infection or vaccination.

Fonville JM, Wilks SH, James SL, Fox A, Ventresca M, Aban M, Xue L, Jones TC, Le NMH, Pham QT, Tran ND, Wong Y, Mosterin A, Katzelnick LC, Labonte D, Le TT, van der Net G, Skepner E, Russell CA, Kaplan TD, Rimmelzwaan GF, Masurel N, de Jong JC, Palache A, Beyer WEP, Le QM, Nguyen TH, Wertheim HFL, Hurt AC, Osterhaus ADME, Barr IG, Fouchier RAM, Horby PW, Smith DJ.

Science. 2014 Nov 21;346(6212):996-1000. doi: 10.1126/science.1256427.

6.

Annual public health and economic benefits of seasonal influenza vaccination: a European estimate.

Preaud E, Durand L, Macabeo B, Farkas N, Sloesen B, Palache A, Shupo F, Samson SI; Vaccines Europe influenza working group.

BMC Public Health. 2014 Aug 7;14:813. doi: 10.1186/1471-2458-14-813.

7.

Seasonal influenza vaccine provision in 157 countries (2004-2009) and the potential influence of national public health policies.

Palache A.

Vaccine. 2011 Nov 28;29(51):9459-66. doi: 10.1016/j.vaccine.2011.10.030. Epub 2011 Oct 21.

8.

Cell-mediated immune responses to inactivated trivalent influenza-vaccination are decreased in patients with common variable immunodeficiency.

van Assen S, de Haan A, Holvast A, Horst G, Gorter L, Westra J, Kallenberg CG, Telgt DS, Palache AM, Giezeman KM, Bijl M.

Clin Immunol. 2011 Nov;141(2):161-8. doi: 10.1016/j.clim.2011.07.004. Epub 2011 Jul 30.

PMID:
21889412
9.

Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis.

Beyer WE, Nauta JJ, Palache AM, Giezeman KM, Osterhaus AD.

Vaccine. 2011 Aug 5;29(34):5785-92. doi: 10.1016/j.vaccine.2011.05.040. Epub 2011 May 30. Review.

PMID:
21624411
10.

Lessons from pandemic influenza A(H1N1): the research-based vaccine industry's perspective.

Abelin A, Colegate T, Gardner S, Hehme N, Palache A.

Vaccine. 2011 Feb 1;29(6):1135-8. doi: 10.1016/j.vaccine.2010.11.042. Epub 2010 Nov 27. Review.

11.

Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study.

Holvast A, van Assen S, de Haan A, Huckriede A, Benne CA, Westra J, Palache A, Wilschut J, Kallenberg CG, Bijl M.

Rheumatology (Oxford). 2009 Oct;48(10):1294-9. doi: 10.1093/rheumatology/kep200. Epub 2009 Aug 19.

PMID:
19692457
12.

Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus.

Holvast A, van Assen S, de Haan A, Huckriede A, Benne CA, Westra J, Palache A, Wilschut J, Kallenberg CG, Bijl M.

Arthritis Rheum. 2009 Aug;60(8):2438-47. doi: 10.1002/art.24679.

13.

Cell-mediated immune responses to influenza vaccination in Wegener's granulomatosis.

Holvast A, de Haan A, van Assen S, Stegeman CA, Huitema MG, Huckriede A, Benne CA, Westra J, Palache A, Wilschut J, Kallenberg CG, Bijl M.

Ann Rheum Dis. 2010 May;69(5):924-7. doi: 10.1136/ard.2009.112813. Epub 2009 Jul 12.

PMID:
19596692
14.

Trivalent inactivated subunit influenza vaccine Influvac: 25-Year experience of safety and immunogenicity.

Giezeman KM, Nauta J, de Bruijn IA, Palache AM.

Vaccine. 2009 Apr 21;27(18):2414-7. doi: 10.1016/j.vaccine.2009.02.008. Epub 2009 Feb 12.

PMID:
19368782
15.

Influenza: a case for an improved link between vaccine research and public health.

Palache AM.

Immunol Lett. 2009 Feb 21;122(2):137. doi: 10.1016/j.imlet.2008.11.010. Epub 2008 Dec 25. No abstract available.

PMID:
19100772
16.

Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination.

Holvast A, Stegeman CA, Benne CA, Huckriede A, Wilschut JC, Palache AM, Kallenberg CG, Bijl M.

Ann Rheum Dis. 2009 Jun;68(6):873-8. doi: 10.1136/ard.2008.092924. Epub 2008 Jul 14. Erratum in: Ann Rheum Dis. 2009 Sep;68(9):1516.

PMID:
18625625
17.

Influenza vaccine dosages.

Palache AM, Beyer WE, Osterhaus AD.

Vaccine. 2008 May 2;26(19):2305-6. doi: 10.1016/j.vaccine.2008.03.007. Epub 2008 Mar 27. No abstract available.

PMID:
18407384
19.

The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad in elderly subjects.

de Bruijn IA, Nauta J, Gerez L, Palache AM.

Vaccine. 2006 Nov 10;24(44-46):6629-31. Epub 2006 Jun 5.

PMID:
16901593
20.

Further evidence for favorable cost-effectiveness of elderly influenza vaccination.

Postma MJ, Baltussen RP, Palache AM, Wilschut JC.

Expert Rev Pharmacoecon Outcomes Res. 2006 Apr;6(2):215-27. doi: 10.1586/14737167.6.2.215.

PMID:
20528557
21.

The virosome concept for influenza vaccines.

Huckriede A, Bungener L, Stegmann T, Daemen T, Medema J, Palache AM, Wilschut J.

Vaccine. 2005 Jul 8;23 Suppl 1:S26-38. Review.

PMID:
16026906
22.

Clinical experience with inactivated, virosomal influenza vaccine.

de Bruijn IA, Nauta J, Cramer WC, Gerez L, Palache AM.

Vaccine. 2005 Jul 8;23 Suppl 1:S39-49.

PMID:
16005120
23.
24.

Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?

Beyer WE, Palache AM, Lüchters G, Nauta J, Osterhaus AD.

Virus Res. 2004 Jul;103(1-2):125-32.

PMID:
15163500
25.

Modeling pandemic preparedness scenarios: health economic implications of enhanced pandemic vaccine supply.

Medema JK, Zoellner YF, Ryan J, Palache AM.

Virus Res. 2004 Jul;103(1-2):9-15.

PMID:
15163482
26.

Haemagglutination-inhibiting antibody to influenza virus.

de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD.

Dev Biol (Basel). 2003;115:63-73. Review.

PMID:
15088777
27.

Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial.

Stephenson I, Nicholson KG, Glück R, Mischler R, Newman RW, Palache AM, Verlander NQ, Warburton F, Wood JM, Zambon MC.

Lancet. 2003 Dec 13;362(9400):1959-66.

PMID:
14683655
28.

Non-responders to egg grown influenza vaccine seroconvert after booster immunization with MDCK cell grown vaccine.

Oxford JS, Al-Jabri AA, Lambkin R, Palache AM, Fleming DM.

Vaccine. 2003 Jun 20;21(21-22):2743-6.

PMID:
12798612
29.

Influenza vaccination in 2000: recommendations and vaccine use in 50 developed and rapidly developing countries.

van Essen GA, Palache AM, Forleo E, Fedson DS.

Vaccine. 2003 May 1;21(16):1780-5.

PMID:
12686094
30.

Influenza virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity.

Huckriede A, Bungener L, ter Veer W, Holtrop M, Daemen T, Palache AM, Wilschut J.

Vaccine. 2003 Feb 14;21(9-10):925-31. Review. No abstract available.

PMID:
12547604
31.
32.

Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity.

Haan L, Verweij WR, Holtrop M, Brands R, van Scharrenburg GJ, Palache AM, Agsteribbe E, Wilschut J.

Vaccine. 2001 Apr 6;19(20-22):2898-907.

PMID:
11282201
34.

Safety, reactogenicity and immunogenicity of Madin Darby Canine Kidney cell-derived inactivated influenza subunit vaccine. A meta-analysis of clinical studies.

Palache AM, Scheepers HS, de Regt V, van Ewijk P, Baljet M, Brands R, van Scharrenburg GJ.

Dev Biol Stand. 1999;98:115-25; discussion 133-4. No abstract available.

PMID:
10494964
35.

Influvac: a safe Madin Darby Canine Kidney (MDCK) cell culture-based influenza vaccine.

Brands R, Visser J, Medema J, Palache AM, van Scharrenburg GJ.

Dev Biol Stand. 1999;98:93-100; discussion 111.

PMID:
10494962
36.

Generation and characterization of reassortant influenza A viruses propagated in serum-free cultured MDCK-SF1 cells.

Voeten JT, Claas EC, Brands R, Palache AM, van Scharrenburg GJ, Rimmelzwaan GF, Osterhaus AD.

Dev Biol Stand. 1999;98:77-87; discussion 89-90.

PMID:
10494961
37.

Characterization of high-growth reassortant influenza A viruses generated in MDCK cells cultured in serum-free medium.

Voeten JT, Brands R, Palache AM, van Scharrenburg GJ, Rimmelzwaan GF, Osterhaus AD, Claas EC.

Vaccine. 1999 Apr 9;17(15-16):1942-50.

PMID:
10217593
38.

Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies.

Beyer WE, de Bruijn IA, Palache AM, Westendorp RG, Osterhaus AD.

Arch Intern Med. 1999 Jan 25;159(2):182-8.

PMID:
9927102
39.

The plea against annual influenza vaccination? 'The Hoskins' Paradox' revisited.

Beyer WE, de Bruijn IA, Palache AM, Westendorp RG, Osterhaus AD.

Vaccine. 1998 Dec;16(20):1929-32.

PMID:
9796045
40.

Influenza vaccines. A reappraisal of their use.

Palache AM.

Drugs. 1997 Dec;54(6):841-56. Review.

PMID:
9421692
41.

Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs.

Palache AM, Brands R, van Scharrenburg GJ.

J Infect Dis. 1997 Aug;176 Suppl 1:S20-3.

PMID:
9240689
42.

Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults.

Beyer WE, Palache AM, Sprenger MJ, Hendriksen E, Tukker JJ, Darioli R, van der Water GL, Masurel N, Osterhaus AD.

Vaccine. 1996 Oct;14(14):1331-9.

PMID:
9004442
43.

Adjuvancy and reactogenicity of N-acetylglucosaminyl-N-acetylmuramyl-dipeptide (GMDP) orally administered just prior to trivalent influenza subunit vaccine. A double-blind placebo-controlled study in nursing home residents.

Palache AM, Beyer WE, Hendriksen E, Gerez L, Aston R, Ledger PW, de Regt V, Kerstens R, Rothbarth PH, Osterhaus AD.

Vaccine. 1996 Oct;14(14):1327-30.

PMID:
9004441
44.

Gender differences in local and systemic reactions to inactivated influenza vaccine, established by a meta-analysis of fourteen independent studies.

Beyer WE, Palache AM, Kerstens R, Masurel N.

Eur J Clin Microbiol Infect Dis. 1996 Jan;15(1):65-70.

PMID:
8641306
45.

Influenza immunization policies in Europe and the United States.

Nicholson KG, Snacken R, Palache AM.

Vaccine. 1995 Mar;13(4):365-9.

PMID:
7793132
46.
47.

Antibody response after influenza immunization with various vaccine doses: a double-blind, placebo-controlled, multi-centre, dose-response study in elderly nursing-home residents and young volunteers.

Palache AM, Beyer WE, Sprenger MJ, Masurel N, de Jonge S, Vardy A, Charpentier B, Noury J, van Beek WC, Borst RJ, et al.

Vaccine. 1993;11(1):3-9.

PMID:
8427034
48.

Improvement of the immunoglobulin subclass response to influenza vaccine in elderly nursing-home residents by the use of high-dose vaccines.

Remarque EJ, van Beek WC, Ligthart GJ, Borst RJ, Nagelkerken L, Palache AM, Sprenger MJ, Masurel N.

Vaccine. 1993;11(6):649-54.

PMID:
8322488
49.

Influenza vaccines: the effect of vaccine dose on antibody response in primed populations during the ongoing interpandemic period. A review of the literature.

Palache AM, Beyer WE, Lüchters G, Völker R, Sprenger MJ, Masurel N.

Vaccine. 1993;11(9):892-908. Review.

PMID:
8212834
50.

Influenza vaccination in asthma.

Palache AM, vd Velden JW.

Lancet. 1992 Mar 21;339(8795):741. No abstract available.

PMID:
1347604

Supplemental Content

Loading ...
Support Center